Last reviewed 2026-04-23 · How we verify

ABT

Abatacept works by inhibiting T-cell activation through the CD80/CD86-CD28 costimulatory pathway.

Abatacept works by inhibiting T-cell activation through the CD80/CD86-CD28 costimulatory pathway. Used for Moderate to severe rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis.

At a glance

Mechanism of action

Abatacept is a selective, high-affinity inhibitor of the CD80/CD86-CD28 interaction. By blocking this interaction, abatacept reduces the activation of T cells, which are a key component of the immune system. This action helps to decrease the severity of autoimmune diseases such as rheumatoid arthritis.

Approved indications

• Moderate to severe rheumatoid arthritis
• Juvenile idiopathic arthritis
• Psoriatic arthritis

Common side effects

• Headache
• Nausea
• Diarrhea
• Fatigue
• Infections

Key clinical trials

• Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm (PHASE2)
• Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (PHASE1)
• Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
• BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (PHASE2)
• Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia (PHASE2)
• Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) (PHASE2)
• Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial) (PHASE2)
• Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.